ATMI — Q1 2013 Earnings Presentation
15 slides from ATMI's earnings presentation, Apr 24, 2013
Slide 1: Q1 2013 Earnings Teleconference
Q1 2013 Earnings Teleconference April 24, 2013 ¢ ATM!
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained herein that relate to ATMI’s future performance, including, without limitation, statements with respect to ATMI’s anticipated results of operations or level of business for 2013 or any other future period, are forward-looking statements within the safe harb
Slide 3: Save The Date: ATMI Analyst Day
Save The Date ATMI Analyst Day Thursday, November 21, 2013 New York, NY For additional information contact: Troy Dewar, CFA Director, Investor Relations 203.207.9349 [email protected] http://investor.atmi.com C A T M |
Slide 4: Q1 2013 Summary
Q1 2013 Summary > Revenues grew 7% Y/Y > Microelectronics improved 6% as implant growth offset lower copper materials > LifeSciences grew 24% on strong single-use equipment and consumable sales > Net income more than doubled > Operating expense management offset lower gross margins > Tax benefit fro
Slide 5: 2013 Strategic Priorities
> > > 2013 Strategic Priorities Grow the business > Microelectronics — advanced nodes at key semiconductor accounts > LifeSciences — biopharmaceutical industry adoption of single-use technology > eVOLV™ — first e-waste recycling licensee is building capacity > BrightBlack® — further develop carbon t
Slide 6: ATMI Q1 2013 financial results
ATMI $M (except per Q1 2013 Revenues by Segment share data) Revenue 99.4 92.6 ™% 100.1 (1%) ™ Microelectronics 89% Gross profit 46.7 44.2 6% 48.8 (4%) m LifeSciences 11% Gross margin 47% 48% 49% Operating income 10.3 | 61 68% | 15.5 (33%) | Q1 2013 Revenues by Geography Operating margin 10% 7% 16% m
Slide 7: Microelectronics
Microelectronics Q1 2013 Revenues by Sector mimplant 30% Revenues 88.1 83.5 6% | 89.1 (1%) mCu Materials 49% Gross margin 48% 50% 50% m Liquid Packaging 15% Operating income 25.2 21.0 20% | 23.4 8% = Other 6% Operating margin 29% 25% 26% > Strong incremental SDS® contribution offset customer materia
Slide 8: LifeSciences
LifeSciences Q1 2013 Revenues by Sector ™ SUT Consumables 34% Revenues 11.3 9.1 24% | 10.9 3% SUT Equipment 16% Gross margin 36% 32% 38% SUT IP 7% Operating income (1.3) (2.1) 41% | 1.3 NM = Sterile Packaging 43% Operating margin (11%) | (23%) 12% > Record revenues on Y/Y increase in demand for sing
Slide 9: Other Financial Data
Other Financial Data Q1 2013 Q1 2012 Q4 2012 Cash and marketable securities 151.1 107.9 168.5 Cash from (used for) operating activities (6.2) 8.7 39.8 Capital Expenditures 8.5 5.3 10.9 Depreciation & Amortization 7.1 6.6 74 Headcount 828 823 817 > Cash balance down due to timing of some payments and
Slide 10: Outlook
Vv Outlook Microelectronics > Wafer starts trending up; full-year 2013 wafer starts up 3-5% > Margin improvement through volume and mix benefit LifeSciences > Confident in our long-term revenue CAGR of 20-30% > GM improving through volume benefit and mix shift to consumables; managing to quarterly p
Slide 11: Thank you for your interest
ry ATM Thank you for your interest. For additional information contact: Troy Dewar, CFA Director, Investor Relations 203.207.9349 [email protected] http://investor.atmi.com ATMI, the ATMI logo, eVOLV, BrightBlack, and SDS are trademarks or registered trademarks of Advanced Technology Materials, Inc.,
Slide 12: Appendix
Appendix ¢ ATM!
Slide 13: ATMI — a technology company enabling Process Efficiency gains for our customers
ATMI —a technology company enabling Process Efficiency gains for our customers Revenues ($M) > Diverse Technology Portfolio > >1,000 patents granted since $367 $390 $407 $414 founding > Formulated and synthesized materials > High-integrity material delivery and 2010 2011 2012 Qi 2013 i processing sy
Slide 14: Microelectronics — enabling technology for semiconductor manufacturing
Microelectronics — enabling technology for semiconductor manufacturing Revenues ($M) $336 $351 $366 $370 2010 2011 2012 Qi 2013 LTM Operating Income ($M)* $94 $98 $109 $114 2010 2011 2012 Qi 2013 L™ Excludes $84.6M charge for contract termination in Q4 2011 Innovative materials and material delivery
Slide 15: LifeSciences — single-use technology partner
LifeSciences — single-use technology partner > Serving critical and cutting-edge life Revenues ($M) ‘ Gath science applications $38 $42 $44 , $31 > Enables product development life cycle optimization > Creates entirely new market segment > Single-use technology (SUT) products 2010 2011 2012 Q1 2013